Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Director | May 16, 2017 | March 29, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date May 16, 2017 · Filed March 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-05-14 | Direct | 250,000 |
Reported balance
After 2017-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-16 · Grant · Acquired 250,000 · Balance 250,000 F1: On May 15, 2017, the Reported Person was granted an option to purchase 250,000 shares of the Issuer's Common Stock, with 50,000 option shares vested as of the date of grant, and the remaining 200,000 shares vesting in twenty-four (24) equal monthly installments measured from May 16, 2017. As of March 26, 2018, 133,333 shares have vested and another 16,666 will vest within 60 days. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2027-11-30 | Direct | 200,000 |
Reported balance
After 2017-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-01 · Grant · Acquired 200,000 · Balance 200,000 F2: On December 1, 2017, the Reported Person was granted an option to purchase 200,000 shares of the Issuer's Common Stock. The option is durational-based, and vests and becomes exercisable in twenty-four (24) successive equal monthly installments, commencing on November 13, 2017. As of March 26, 2018, 33,333 shares have vested and another 16,666 will vest within 60 days, and Dr. Schmitz has not exercised any stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 15, 2017, the Reported Person was granted an option to purchase 250,000 shares of the Issuer's Common Stock, with 50,000 option shares vested as of the date of grant, and the remaining 200,000 shares vesting in twenty-four (24) equal monthly installments measured from May 16, 2017. As of March 26, 2018, 133,333 shares have vested and another 16,666 will vest within 60 days.
F2: On December 1, 2017, the Reported Person was granted an option to purchase 200,000 shares of the Issuer's Common Stock. The option is durational-based, and vests and becomes exercisable in twenty-four (24) successive equal monthly installments, commencing on November 13, 2017. As of March 26, 2018, 33,333 shares have vested and another 16,666 will vest within 60 days, and Dr. Schmitz has not exercised any stock options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2017 Filed Mar 29, 2018 00:30 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001683168-18-000790 · schmitz_frm4.xml · derivative · entry 2 Schmitz Stephen Martin · CIK 0001735902 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-11-30 F2 · derivative.underlying_shares: On December 1, 2017, the Reported Person was granted an option to purchase 200,000 shares of the Issuer's Common Stock. The option is durational-based, and vests and becomes exercisable in twenty-four (24) successive equal monthly installments, commencing on November 13, 2017. As of March 26, 2018, 33,333 shares have vested and another 16,666 will vest within 60 days, and Dr. Schmitz has not exercised any stock options. Read SEC document |
| May 16, 2017 Filed Mar 29, 2018 00:30 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001683168-18-000790 · schmitz_frm4.xml · derivative · entry 1 Schmitz Stephen Martin · CIK 0001735902 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-05-14 F1 · derivative.underlying_shares: On May 15, 2017, the Reported Person was granted an option to purchase 250,000 shares of the Issuer's Common Stock, with 50,000 option shares vested as of the date of grant, and the remaining 200,000 shares vesting in twenty-four (24) equal monthly installments measured from May 16, 2017. As of March 26, 2018, 133,333 shares have vested and another 16,666 will vest within 60 days. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.